Repurposing of Ring Framework through TR screening

TL;DR

This paper presents a novel TR dual screening method for drug repurposing that identifies and optimizes rarely used ring systems from FDA-approved drugs, leading to the discovery of a new RARbeta agonist.

Contribution

Introduces the TR dual screening approach for repurposing drug ring systems, enabling targeted optimization and biological validation of new therapeutic candidates.

Findings

RARbeta and cyproheptadine identified as a target-ring pair

Compound 6c proved to be a RARbeta agonist

Method facilitates selection of compounds with favorable ADMET profiles

Abstract

In the drug repurposing approach, the chemically diverse and potentially safe molecules can be explored as therapeutic potential out of those originally targeted indications. However, the intellectual property rights, and competitive over-heating issue from sharing the same drug pipeline information are drawback of the approach. In current paradigm of drug discovery, despite approval of new chemical entity, the finding of a new ring system for drug discovery have stagnated. In addition, there are still rarely used ring systems from FDA approved drug that can be optimized and used for repurposing purpose. In the present work, these rarely used drug ring system were re-purposed with our bidirectional target and ring screening (TR- dual screening) approach within our defined objectives. The TR-dual screening suggested RARbeta and cyproheptadine as a pair of target and ring system. The selected ring system was virtually grown with predefined criterion, ranking of molecular docking and top score poses made us select test compounds for synthesis and biological proof. Among the tested compounds, 6c proved RARbeta agonist activity. The concept of TR dual optimization can contribute to picking either a compound having acceptable ADMET profile or a target for a selected drug scaffold.